© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
October 13, 2021
Oxurion NV announced Wednesday the first patient to be dosed in the INTEGRAL phase 2 clinical study evaluating THR-687 as a treatment for patients with DME.
October 12, 2021
Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
October 11, 2021
David Boyer, MD, reports on the use of pegcetacoplan to treat geographic atrophy when administered monthly or every-other-month regimens in the phase 3 DERBY and OAKS studies.
October 11, 2021
Arshad Khanani, MD, MA, reports primary study findings from the phase 3 study on the Port Delivery System with ranibizumab.
October 10, 2021
Richard B. Rosen, MD, DSc(Hon), reports on the capabilities of using clinical OCT for imaging and measuring macular surface macrophage cells during the 2021 ASRS annual meeting.
October 10, 2021
Justis P. Ehlers, MD, speaks on the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.
October 10, 2021
Sunir Garg, MD, reports on the risk of presumed infectious endophthalmitis following administration of anti-VEFG injections in correlation with universal masking.
October 10, 2021
Yoshihiro Yonekawa, MD, reports on the findings of an investigation looking at the prevalence of endophthalmitis following minimally invasive glaucoma surgery.
October 10, 2021
Alcon's Paul Hallen offers a look at the highlights from the 2021 ASRS annual meeting's OIS panel as well as the company's latest innovations.
October 09, 2021
Rishi Singh, MD, reports on results from the VISTA and VIVID studies analyzing the use of intravitreal aflibercept injections to treat DME.
